Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival

Executive Summary

Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
Advertisement

Related Content

PDUFA IV Fix For FDA Performance On Standard Reviews Advocated By BIO
PDUFA IV Fix For FDA Performance On Standard Reviews Advocated By BIO
Taxotere Sales Force Restructured To Bolster Growth, Fend Off Competition
Taxotere Sales Force Restructured To Bolster Growth, Fend Off Competition
Aventis Taxotere Approved For Breast Cancer; Lowers Relapse Chance 25.7%
Aventis Taxotere Approved For Breast Cancer; Lowers Relapse Chance 25.7%
Oncology Drug Development Not Advanced By Non-Inferiority Trials – Pazdur
Oncology Drug Development Not Advanced By Non-Inferiority Trials – Pazdur
Lilly Alimta Lung Cancer Use Supported By FDA Cmte.; Safety Profile Cited
Lilly Alimta $3,900 Per Course Of Therapy, Available In Two Weeks

Topics

Advertisement
UsernamePublicRestriction

Register

PS044548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel